Stockscreener 앱 받기
1.23
5.38%
-0.07
시간 외 거래:
1.25
0.02
+1.63%
전일 마감가:
$1.30
열려 있는:
$1.25
하루 거래량:
46,662
Relative Volume:
0.20
시가총액:
$51.70M
수익:
-
순이익/손실:
$-8.82M
주가수익비율:
-4.10
EPS:
-0.3
순현금흐름:
$-18.01M
1주 성능:
-6.82%
1개월 성능:
+16.04%
6개월 성능:
+42.20%
1년 성능:
+8.85%
1일 변동 폭
$1.2052
$1.25
1주일 범위
$0.97
$1.52
52주 변동 폭
$0.7301
$3.15
Estrella Immunopharma Inc Stock (ESLA) Company Profile
명칭
Estrella Immunopharma Inc
전화
(510) 318-9098
주소
5858 HORTON STREET, SUITE 370, EMERYVILLE
Compare ESLA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
1.23 | 54.64M | 0 | -8.82M | -18.01M | -0.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Estrella Immunopharma Inc 주식(ESLA)의 최신 뉴스
Portfolio Update: Will Estrella Immunopharma Inc benefit from government policy2025 Growth vs Value & Accurate Intraday Trade Tips - baoquankhu1.vn
Estrella reports 100% complete response rate in lymphoma trial By Investing.com - Investing.com South Africa
Merger Talk: Is INFA a strong growth stock2025 Dividend Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL - Yahoo Finance
D. Boral Capital Reiterates Buy Rating for Estrella Immunopharma (NASDAQ:ESLA) - MarketBeat
Estrella reports 100% complete response rate in lymphoma trial - Investing.com
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR® - Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT(R) & CIBMTR(R) - marketscreener.com
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR - BioSpace
Estrella to present phase 1 data on CD19-targeted cell therapy - Investing.com Canada
Estrella to present phase 1 data on CD19-targeted cell therapy By Investing.com - Investing.com South Africa
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR® - Yahoo Finance
Market Moves: Does Estrella Immunopharma Inc stock have upside surprise potentialBear Alert & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Market Recap: Should I invest in Marvell Technology Inc before earnings2025 Investor Takeaways & Short-Term Swing Trade Alerts - baoquankhu1.vn
ESLA Analyst Rating: Target Price Cut by 50% to $8 | ESLA Stock News - GuruFocus
Rally Mode: How much upside does Estrella Immunopharma Inc have2025 Risk Factors & High Accuracy Swing Trade Signals - baoquankhu1.vn
How much upside does Estrella Immunopharma Inc have2025 Risk Factors & High Accuracy Swing Trade Signals - baoquankhu1.vn
Is Estrella Immunopharma Inc. stock overvalued or fairly pricedWeekly Stock Report & Daily Volume Surge Signals - bollywoodhelpline.com
Panic Selling: Is Estrella Immunopharma Inc stock a hidden gemWeekly Profit Analysis & Breakout Confirmation Trade Signals - baoquankhu1.vn
Market Outlook: Will Estrella Immunopharma Inc benefit from government policyJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Estrella Immunopharma receives Nasdaq notice for delayed annual meeting By Investing.com - Investing.com Nigeria
Estrella Immunopharma receives Nasdaq notice for delayed annual meeting - Investing.com
Estrella Immunopharma Receives Nasdaq Non-Compliance Notice - TipRanks
Estrella Immunopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Day Trade: What insider trading reveals about Estrella Immunopharma Inc stock2025 Investor Takeaways & Expert Curated Trade Setups - Bộ Nội Vụ
Is Estrella Immunopharma Inc. stock a good choice for value investors2025 Dividend Review & Fast Gain Swing Alerts - Улправда
How Estrella Immunopharma Inc. stock trades during market volatilityWeekly Trend Recap & Safe Entry Trade Reports - ulpravda.ru
How risky is Estrella Immunopharma Inc. stock nowPortfolio Value Summary & Technical Buy Zone Confirmations - ulpravda.ru
Estrella Immunopharma, Inc.Warrant (NQ: ESLAW - FinancialContent
Is Estrella Immunopharma Inc. stock a smart buy before Fed meetingWeekly Volume Report & Long-Term Growth Stock Strategies - Улправда
Can Estrella Immunopharma Inc. stock sustain market leadershipWatch List & Short-Term Trading Alerts - ulpravda.ru
Is Estrella Immunopharma Inc. stock attractive for passive investors2025 Geopolitical Influence & Accurate Intraday Trading Signals - ulpravda.ru
Published on: 2026-01-07 23:18:22 - Улправда
How interest rate cuts could boost Estrella Immunopharma Inc. stockSector Leadership Analysis & Small Capital Trading Growth - Улправда
Estrella Immunopharma Secures $8 Million in Funding to Advance Cancer Therapy Programs - citybuzz -
Estrella Immunopharma completes $8M direct offering financing - TipRanks
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement - MEXC
Estrella Immunopharma Signs Multiple Material Agreements - TradingView
Estrella Immunopharma closes $8 million registered direct offering - Investing.com
Estrella Immunopharma closes $8 million registered direct offering By Investing.com - Investing.com India
Estrella Immunopharma raises $8 million through registered offering By Investing.com - Investing.com Nigeria
Estrella Immunopharma stock falls after announcing $8 million offering By Investing.com - Investing.com Nigeria
Estrella Immunopharma stock falls after announcing $8 million offering - Investing.com India
Estrella Immunopharma raises $8 million through registered offering - Investing.com
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - The AI Journal
Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Grows By 28.5% - MarketBeat
Aug Levels: How Estrella Immunopharma Inc stock reacts to global recession fearsMarket Performance Recap & Low Drawdown Momentum Trade Ideas - Bộ Nội Vụ
Estrella Immunopharma (ESLAW) Stock Analysis Report | Financials & Insights - Benzinga
Estrella Immunopharma shares gain as CD19 cancer therapy progresses into phase II - MSN
Estrella Immunopharma offers up to 2.5 mln shares for resale by selling stockholders - marketscreener.com
Estrella Immunopharma Inc (ESLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):